MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Core Viewpoint - MediciNova, Inc. has received a Notice of Allowance for a patent covering MN-166 (ibudilast) for treating post-COVID conditions, which may provide therapeutic options for a range of symptoms experienced by patients recovering from COVID-19 [1][2]. Group 1: Patent and Drug Development - The patent allows for various administration methods of MN-166, including oral, intravenous, subcutaneous, intramuscular, and inhalation, with a wide range of dosing frequencies and treatment periods [2]. - The patent is expected to expire no earlier than November 2042, providing a long exclusivity period for the company [2]. - MN-166 is currently in late-stage clinical development for neurodegenerative diseases and is also being evaluated for Long COVID and other conditions [4][5]. Group 2: Clinical Trials and Collaborations - MediciNova is collaborating with the University Health Network in Canada for a Phase 2/3 clinical trial focused on Long COVID, indicating a commitment to addressing post-COVID health challenges [3]. - The company plans to apply for a New Drug Application contingent on positive outcomes from ongoing studies, demonstrating a proactive approach to drug development [3]. Group 3: Company Overview - MediciNova is a clinical-stage biopharmaceutical company with a pipeline of therapies targeting inflammatory, fibrotic, and neurodegenerative diseases, with 11 programs currently in clinical development [5]. - The lead asset, MN-166, is in Phase 3 trials for ALS and DCM, and is Phase 3-ready for progressive MS, showcasing the company's focus on serious health conditions [5].